Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).

被引：5
作者：
Sayala, Hazem A.
Moreton, Paul
Jones, Richard A.
Rawstron, Andy C.
O'Connor, Sheila J.
Evans, Paul
Anthony, Carter
Dearden, Claire
Matutes, Estella
Pettitt, Andrew R.
Kennedy, Daniel B.
Hillmen, Peter
机构：
[1] Leeds Gen Infirm, Haematol Malignacy Diag Serv, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
[3] Canc Res Inst, London, England
[4] Leicester Royal Infirm, Leicester, Leics, England
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.34.34
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
34
引用
收藏
页码：14A / 15A
页数：2
相关论文
共 50 条
[11]   Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL study group [J].
Elter, T. ;
James, R. ;
Wendtner, C. M. ;
Stilgenbauer, S. ;
Winkler, D. ;
Ritgen, M. ;
Hallek, M. ;
Engert, A. .
ANNALS OF ONCOLOGY, 2008, 19 :194-194
[12]   Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group [J].
Elter, T. ;
James, R. ;
Wendtner, C. M. ;
Stilgenbauer, S. ;
Winkler, D. ;
Ritgen, M. ;
Hallek, M. ;
Engert, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[13]   Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia [J].
不详 .
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03) :202-203
[14]   Concomitant treatment of patients with relapsed/refractory CLL using a combination of fludarabine and alemtuzumab is highly effective: Final results of a phase-II study. [J].
Engert, A ;
Elter, T ;
Borchmann, P ;
Schulz, H ;
Reiser, M ;
Trelle, S ;
Staib, P ;
Schinkoethe, T ;
Hallek, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :574S-574S
[15]   Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC) [J].
Bosch, Francesc ;
Abrisqueta, Pau ;
Villamor, Neus ;
Jose Terol, Maria ;
Gonzalez-Barca, Eva ;
Gonzalez, Marcos ;
Ferra, Christelle ;
Abella, Eugenia ;
Delgado, Julio ;
Garcia-Marco, Jose A. ;
Gonzalez, Yolanda ;
Carbonell, Felix ;
Ferrer, Secundino ;
Monzo, Encarna ;
Jarque, Isidro ;
Muntanola, Ana ;
Constants, Mireia ;
Escoda, Lourdes ;
Montserrat, Emili .
BLOOD, 2011, 118 (21) :136-137
[16]   Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG) [J].
Stilgenbauer, S ;
Kröber, A ;
Winkler, D ;
Kienle, D ;
Busch, R ;
Hallek, M ;
Hensel, M ;
Lengfelder, E ;
Trümper, L ;
Dreger, P ;
Jäger, U ;
Döhner, H .
ANNALS OF ONCOLOGY, 2005, 16 :43-43
[17]   Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study [J].
Montillo, Marco ;
Tedeschi, Alessandra ;
Ricci, Francesca ;
Zaccaria, Alfonso ;
Crugnola, Monica ;
Spriano, Mauro ;
Spedini, PierAngelo ;
Ilariucci, Fiorella ;
Uziel, Lilj ;
Attolico, Immacolata ;
De Blasio, Angelo ;
Vismara, Eleonora ;
Morra, Enrica ;
Petrizzi, Valeria Belsito .
BLOOD, 2010, 116 (21) :595-596
[18]   Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL):: results of a phase II study of the German CLL Study Group [J].
Hallek, M ;
Schmitt, B ;
Wilhelm, M ;
Busch, R ;
Kröber, A ;
Fostitsch, HP ;
Sezer, O ;
Herold, M ;
Knauf, W ;
Wendtner, CM ;
Kuse, R ;
Freund, M ;
Franke, A ;
Schriever, F ;
Nerl, C ;
Döhner, H ;
Thiel, E ;
Hiddemann, W ;
Brittinger, G ;
Emmerich, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :342-348
[19]   Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL. [J].
Khan, K. D. ;
O'Brien, S. ;
Rai, K. R. ;
Brown, J. R. ;
Abboud, C. ;
Hurd, D. D. ;
Conkling, P. ;
Yang, Z. ;
Haltom, E. J. ;
Uprichard, M. J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :360S-360S
[20]   Phase II trial of the diphtheria fusion protein ONTAK in patients with fludarabine refractory chronic lymphocytic leukemia (CLL). [J].
Frankel, AE ;
Patrick, CL ;
Powell, BL .
BLOOD, 2001, 98 (11) :289B-289B
12345